Detecting soluble Clusterin in in-vitro and in-vivo models of prostate cancer

Neoplasma

Volumn 57, Issue 5, 2010, Pages 488-493

  Girard, F P ^a,b   Byrne, J ^a   Downes, M ^a   Fanning, D ^a   Desgrandchamps, F ^b   Fitzpatrick, J M ^a   Watson, R W ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Biological marker; Clusterin; Prognostic; Prostate cancer

Indexed keywords

CLUSTERIN; DOCETAXEL; CLU PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CLINICAL ARTICLE; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING; BLOOD; CHEMISTRY; MIDDLE AGED; PROSTATE TUMOR; TUMOR CELL LINE; URINE;

AGED; CELL LINE, TUMOR; CLUSTERIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952113770     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_05_488     Document Type: Article

References (24)

1. HEIDENREICH A, AUS G, BOLLA M, JONIAU S, MATVEEV VB, et al. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol. 2008; 53: 68-80 doi:10.1016/ j.eururo.2007.09.002
2. BYRNE JC, DOWNES MR, O'DONOGHUE N, O'KEANE C, O'NEILL A et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res. 2009; 8: 942-57. doi:10.1021/pr800570s
3. COCHRANE DR, WANG Z, MURAMAKI M, GLEAVE ME, NELSON CC. Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem. 2007; 282(4): 2278-87. doi:10.1074/jbc.M608162200
4. KAPRON JT, HILLIARD GM, LAKINS JN, TENNISWOOD MP, WEST KA. Identification and characterization of glycosylation sites in human serum clusterin. Protein Sci. 1997; 6: 2120-33. doi:10.1002/pro.5560061007 143570
5. AMMAR H, CLOSSET JL. Clusterin activates survival through the PI-3 kinase/Akt pathway. J. Biol. Chem. 2008; 283: 12851-12861. doi:10.1074/jbc.M800403200
6. ZHANG H, KIM JK, EDWARDS CA, XU Z, TAICHMAN R et al. Clusterin inhibits[apoptosis by interacting with activated bax. Nature Cell Biology 2005; 7: 909-915. doi:10.1038/ncb1291
7. YANG CR, LESKOV K, HOSLEY-EBERLEIN K, CRISWELL T, PINK JJ et al. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Cell Biologie 2000; 97: 5907-5912.
8. LESKOV KS, DMITRY Y, BOOTHMAN, KINSELLA TJ, BOOTHMAN DA. Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein. The Journal of Biological Chemistry 2003; 278: 11590-11600. doi:10.1074/jbc. M209233200
9. CACCAMO AE, DESENZANI S, BELLONI L, BORGHETTI AF, BETTUZZI S. Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells. J Cell Physiol. 2006; 207: 208-19. doi:10.1002/ jcp.20561
10. ROBERT W, BAILEY A, DUNKER K, GARNER EC, GRISWOLD MD. Clusterin, a[binding protein with a molten globule-like region. Biochemistry 2001; 40: 11828-840. doi:10.1021/bi010135x
11. TROUGAKOS IP, GONOS ES. Clusterin/Apolipoprotein J in human aging and cancer. The international journal of biochemistry & Cell biology 2002; 34: 1430-1448. doi:10.1016/ S1357-2725(02)00041-9
12. YOO J, PARK SS, LEE YJ. Pretreatment of docetaxel enhances TRAIL-mediates apoptosis in prostate cancer cells. J Cell Biochem. 2008; 104: 1636-46. doi:10.1002/jcb.21729
13. PARK DC, YEO SG, WILSON MR, YERBURY JJ, KWONG J. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in Ovarian cancer. Neoplasia. 2008; 10: 964-72.
14. PATTERSON SG, WEI S, CHEN X, SALLMAN DA, GILVARY DL. Novel role of STAT1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 2006; 6113-6122.
15. NIZARD P, TETLEY S, LE DRÉAN Y, WATRIN T, LE GOFF P. Stress-Induced retro translocation of Clusterin /ApoJ into the Cytosol. Traffic 2007; 8: 554-565. doi:10.1111/j.1600-0854.2007.00549.x
16. MARTINEAU JC, GREEN DR. Breaking the mitochiondrial barrier. Nature reviews, Molecular cell biol. 2001; 2: 63-67. doi:10.1038/35048069
17. STEWART EM, AQUILINA JA, EASTERBROOK-SMITH SB, MURPHY-DURLAND D, JACOBSEN C. Effects of glycosylation on the structure and function of the extracellular chaperone clusterin. Biochemistry 2007; 46: 1412-22.
18. PUCCI S, BONANNO E, PICHIORRI F, ANGELONI C, SPAGNOLI LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298-304. doi:10.1038/sj.onc.1207404
19. SCALTRITI M, BRAUSI M, AMOROSI A, CAPORALI A, D'ARCA D et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low-and high-grade human prostate cancer. Int J Cancer. 2004 Jan 1; 108: 23-30. doi:10.1002/ijc.11496
20. KRÜGER S, MAHNKEN A, KAUSCH I, FELLER AC. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006; 67: 105-109. doi:10.1016/j.urology.2005.04.043
21. STEJSKAL D, FIALA RR. Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma. 2006; 53: 343-6.
22. SOLICHOVAA P, KARPISEK M, OCHMANOVA R, HANULOVA Z, HUMENANSKA V et al. Urinary clusterin concentrations A possible marker of nephropathy? Pilot Study Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007; 151: 233-236.
23. MORRISSEY C, LAKINS J, MOQUIN A, HUSSAIN M, TENNISWOOD M. An antigen capture assay for the measurement of serum clusterin concentrations. Biochem Biophys Methods. 2001 Mar 28; 48: 13-21. doi:10.1016/S0165-022X(00)00137-8
24. BROWN JA, RODIN DM, HARISINGHANI M, DAHL DM. Impact of preoperative endorectal MRI stage classification on neurovascular bundle sparing aggressiveness and the radical[prostatectomy positive margin rate. Urol Oncol. 2009; 27: 174-9. doi:10.1016/j.urolonc.2008.04.009